Published in Int Wound J on September 01, 2006
Comparison of EGF with VEGF non-viral gene therapy for cutaneous wound healing of streptozotocin diabetic mice. Diabetes Metab J (2011) 0.78
Syndesome Therapeutics for Enhancing Diabetic Wound Healing. Adv Healthc Mater (2016) 0.76
Intralesional epidermal growth factor for diabetic foot wounds: the first cases in Turkey. Diabet Foot Ankle (2015) 0.76
Biomaterials and Nanotherapeutics for Enhancing Skin Wound Healing. Front Bioeng Biotechnol (2016) 0.75
Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers. BMC Pharmacol Toxicol (2013) 0.75
Thrombolysis as first choice therapy in prosthetic heart valve thrombosis. A study of 68 patients. J Thromb Thrombolysis (2006) 1.30
A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine (2006) 1.24
Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines (2010) 1.10
The pro-inflammatory environment in recalcitrant diabetic foot wounds. Int Wound J (2008) 1.08
Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies. BMC Cancer (2009) 1.02
Epidermal growth factor in clinical practice - a review of its biological actions, clinical indications and safety implications. Int Wound J (2009) 1.00
Primary and secondary infections of Macaca fascicularis monkeys with Asian and American genotypes of dengue virus 2. Clin Vaccine Immunol (2007) 0.97
Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res (2006) 0.94
A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology (2009) 0.93
Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins. Arch Virol (2008) 0.93
The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model. Viral Immunol (2009) 0.88
Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. Am J Trop Med Hyg (2003) 0.87
A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J Virol Methods (2004) 0.87
Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor. J Immunol (2006) 0.87
Viremia and the magnitude of the immune response upon infection of green monkeys with dengue virus type 2 are strain-dependent. Curr Microbiol (2009) 0.86
Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study. Int Wound J (2009) 0.85
Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis. Vaccine (2008) 0.85
Viremia and antibody response in green monkeys (Chlorocebus aethiops sabaeus) infected with dengue virus type 2: a potential model for vaccine testing. Microbiol Immunol (2009) 0.85
Characterization of the immunoreactivity of anti-interferon alpha antibodies in myasthenia gravis patients. Epitope mapping. J Autoimmun (2004) 0.84
The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2. Clin Vaccine Immunol (2011) 0.83
A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice. Biotechnol Appl Biochem (2004) 0.83
Attenuation of internal organ damages by exogenously administered epidermal growth factor (EGF) in burned rodents. Burns (2002) 0.83
Ubiquitous expression of human SCA2 gene under the regulation of the SCA2 self promoter cause specific Purkinje cell degeneration in transgenic mice. Neurosci Lett (2005) 0.82
Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use. Int J Infect Dis (2009) 0.82
Antibodies induced by dengue virus type 1 and 2 envelope domain III recombinant proteins in monkeys neutralize strains with different genotypes. Clin Vaccine Immunol (2009) 0.82
Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction. Clin Sci (Lond) (2007) 0.82
Construction, purification, and characterization of a chimeric TH1 antagonist. BMC Biotechnol (2006) 0.81
A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus. Vaccine (2006) 0.81
Interferon alpha-2b as adjuvant treatment of recurrent respiratory papillomatosis in Cuba: National Programme (1994-1999 report). J Laryngol Otol (2004) 0.81
Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus. Virus Res (2008) 0.81
The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice. Vaccine (2011) 0.80
Enzyme-linked immunosorbent assay for quantitative determination of capsular polysaccharide production in Streptococcus pneumoniae clinical isolates. Biotechnol Appl Biochem (2006) 0.80
In vitro assembly of nucleocapsid-like particles from purified recombinant capsid protein of dengue-2 virus. Arch Virol (2009) 0.80
Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice. Int Immunol (2009) 0.80
Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors. Vaccine (2005) 0.80
Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure. Clin Sci (Lond) (2006) 0.80
Bioequivalence of two recombinant granulocyte colony-stimulating factor formulations in healthy male volunteers. Biopharm Drug Dispos (2005) 0.79
Purified and highly aggregated chimeric protein DIIIC-2 induces a functional immune response in mice against dengue 2 virus. Arch Virol (2012) 0.79
Identification and characterization of phage-displayed peptide mimetics of Neisseria meningitidis serogroup B capsular polysaccharide. Int J Med Microbiol (2010) 0.78
Angiographic patency study of an albumin-free recombinant streptokinase formulation in acute myocardial infarction. J Pharm Pharm Sci (2004) 0.78
Outer membrane vesicles of the VA-MENGOC-BC vaccine against serogroup B of Neisseria meningitidis: Analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry. Proteomics (2006) 0.78
Effect of conjugation methodology on the immunogenicity and protective efficacy of meningococcal group C polysaccharide-P64k protein conjugates. FEMS Immunol Med Microbiol (2004) 0.78
The fusion site of envelope fragments from each serotype of Dengue virus in the P64k protein, influence some parameters of the resulting chimeric constructs. Biochem Biophys Res Commun (2003) 0.78
Olive baboons: a non-human primate model for testing dengue virus type 2 replication. Int J Infect Dis (2013) 0.77
Study of various presentation forms for a peptide mimetic of Neisseria meningitidis serogroup B capsular polysaccharide. Bioconjug Chem (2010) 0.77
Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice. Biotechnol Appl Biochem (2009) 0.77
A tetravalent dengue vaccine containing a mix of domain III-P64k and domain III-capsid proteins induces a protective response in mice. Arch Virol (2014) 0.77
Expression in Pichia pastoris and immunological evaluation of a truncated Dengue envelope protein. Mol Biotechnol (2007) 0.77
Recombinant nucleocapsid-like particles from dengue-2 induce functional serotype-specific cell-mediated immunity in mice. J Gen Virol (2012) 0.77
Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus. Microbiol Immunol (2014) 0.77
Purified capsular polysaccharide of Neisseria meningitidis serogroup A as immune potentiator for antibody production. Curr Microbiol (2009) 0.76
Generation and characterization of potential dengue vaccine candidates based on domain III of the envelope protein and the capsid protein of the four serotypes of dengue virus. Arch Virol (2014) 0.76
Influence of aluminum-based adjuvant on the immune response to multiantigenic formulation. Viral Immunol (2006) 0.76
Proteomic study via a non-gel based approach of meningococcal outer membrane vesicle vaccine obtained from strain CU385: a road map for discovering new antigens. Hum Vaccin (2009) 0.76
Comparison of three ELISA protocols to measure antibody responses elicited against serogroup C meningococcal polysaccharide in mouse, monkey and human sera. J Microbiol Methods (2005) 0.76
Streptokinase for the treatment of acute ischaemic stroke : towards better strategies. CNS Drugs (2003) 0.75
The serogroup A capsular polysaccharide from Neisseria meningitidis enhances the cell-mediated immunity and the protective capacity induced by a dengue fusion protein in mice. Arch Virol (2012) 0.75
Gonadotrophin releasing hormone-based vaccine, an effective candidate for prostate cancer and other hormone-sensitive neoplasms. Adv Exp Med Biol (2008) 0.75
Serotype specificity of recombinant fusion protein containing domain III and capsid protein of dengue virus 2. Antiviral Res (2012) 0.75
Immunologic memory response induced by a meningococcal serogroup C conjugate vaccine using the P64k recombinant protein as carrier. FEMS Immunol Med Microbiol (2006) 0.75
Nucleocapsid-like particles of dengue-2 virus enhance the immune response against a recombinant protein of dengue-4 virus. Arch Virol (2010) 0.75
Multiple artery aneurysms found during acute coronary syndrome investigation: an unreported association. Clinics (Sao Paulo) (2007) 0.75
Immunoglobulin E-dependent regulation of the CCR3 chemokine receptor by interferon-gamma in atopic asthmatics. Int Arch Allergy Immunol (2008) 0.75
Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. Eur J Pharm Sci (2012) 0.75
Safety and preliminary immunogenicity of MenC/P64k, a meningococcal serogroup C conjugate vaccine with a new recombinant carrier. FEMS Immunol Med Microbiol (2006) 0.75
Early Identification of the Patient with Endotheliopathy of Trauma by Arrival Serum Albumin. Shock (2017) 0.75